Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewResveratrol
Description: Cyclooxygenase inhibitor
Chemical Name: 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol
Purity: ≥98% (HPLC)
Biological Activity for Resveratrol
Resveratrol is a phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Inhibits cytochrome P450 1A1 (IC50 = 23 μM) and displays mixed agonist/antagonist actions at ERα and ERβ estrogen receptors. Converted into the anticancer agent piceatannol (Cat. No. 1554) by cytochrome P450 1B1. Activates autophagy. Also activates TRPA1 in prostate cancer-associated fibroblasts. Also SIRT1 activator.
Compound Libraries for Resveratrol
Resveratrol is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library and Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.
Technical Data for Resveratrol
| M. Wt | 228.25 |
| Formula | C14H12O3 |
| Storage | Desiccate at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 501-36-0 |
| PubChem ID | 445154 |
| InChI Key | LUKBXSAWLPMMSZ-OWOJBTEDSA-N |
| Smiles | OC1=CC=C(C=C1)\C=C\C1=CC(O)=CC(O)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Resveratrol
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| ethanol | 100 | ||
| DMSO | 22.82 | 100 |
Preparing Stock Solutions for Resveratrol
The following data is based on the product molecular weight 228.25. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.38 mL | 21.91 mL | 43.81 mL |
| 5 mM | 0.88 mL | 4.38 mL | 8.76 mL |
| 10 mM | 0.44 mL | 2.19 mL | 4.38 mL |
| 50 mM | 0.09 mL | 0.44 mL | 0.88 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Resveratrol
References for Resveratrol
References are publications that support the biological activity of the product.
Baur and Sinclair (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat.Rev.Drug Discov. 5 493 PMID: 16732220
Bowers et al (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology 141 3657 PMID: 11014220
Chun et al (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem.Biophys.Res.Commun. 262 20 PMID: 10448061
Fremont (2000) Biological effects of resveratrol. Life Sci. 66 663 PMID: 10680575
Kimura et al (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim.Biophys.Acta 834 275 PMID: 3922423
Baptista et al (2013) Regulation of histone H2A.Z exprsesion is mediated by sirtuin 1 in prostate cancer. Oncotarget 4 1673 PMID: 24127549
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
Vancauwenberghe et al (2017) Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts (CAF). Mol.Carcinog. 56 1851 PMID: 28277613
If you know of a relevant reference for Resveratrol, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Resveratrol, Resveratrol supplier, Antitumor, anti-oxidant, agent, Cyclooxygenase, inhibitors, inhibits, COX, Oxygenases, Oxidases, Antiangiogenics, Antioxidants, Class, III, HDACs, (Sirtuins), Autophagy, TRPA1, 1418, Tocris Bioscience
7 Citations for Resveratrol
Citations are publications that use Tocris products. Selected citations for Resveratrol include:
Pacholec et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285 8340 PMID: 20061378
Meftahi et al (2015) Suppressive Effects of Resveratrol Treatment on The Intrinsic Evoked Excitability of CA1 Pyramidal Neurons. Evid Based Complement Alternat Med 17 532 PMID: 26464825
Ohshiro et al (2007) Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Br J Pharmacol 67 8164 PMID: 17804729
Chen et al (2014) A critical role for IF. regulatory factor 9 in cerebral ischemic stroke. J Neurosci 34 11897 PMID: 25186738
Rojas et al (2014) Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci 8 24 PMID: 24570655
Jiang and Zsombok (2014) Regulation of neurons in the dorsal motor nucleus of the vagus by SIRT1. Front Neurosci 7 270 PMID: 24454277
Wang et al (2013) Active Constituents from Liriope platyphylla Root against Cancer Growth In Vitro. Cancer Res 2013 857929 PMID: 23762164
Do you know of a great paper that uses Resveratrol from Tocris? Please let us know.
Reviews for Resveratrol
There are currently no reviews for this product. Be the first to review Resveratrol and earn rewards!
Have you used Resveratrol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.